bioRxiv / medRxiv
open access
CC BY-NC-ND 4.0
Quantifying MS Progression in the Era of Highly Effective Therapy: Trial Design Implications
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Quantitative data related to the MS#343164
- Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).#910159
- Dry Needling for Treating Spasticity in Multiple Sclerosis#898537
- Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease#877855
- Therapy Optimization in Multiple Sclerosis (MS)#873601
Record · ID 261200
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive